ProKidney Corp.
NASDAQ:PROKBiotechnology
+$0.02 today
- Market cap
- $349.70M
- Beta
- 1.70
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$0.53
Volume 1.80M
Average 0.96M
PROK Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
ProKidney Corp.NASDAQ: PROK
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $1.44M fell 10.3% year over year, behind the +1.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.0% from the prior quarter. Over 3 fiscal years it compounded at +29.4% a year.
Context
- Depreciation & amortization amounted to 736.3% of revenue in FY2025, down 6411.1 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -10.3% toward the trailing-twelve-month pace of +1.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 6.58M USD
- Year-over-year change
- +21.0%
- 4-year CAGR
- +34.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.58M | +21.0% |
| FY2024 | 2024-12-31 | 5.43M | +41.0% |
| FY2023 | 2023-12-31 | 3.85M | +26.9% |
| FY2022 | 2022-12-31 | 3.04M | +53.0% |
| FY2021 | 2021-12-31 | 1.98M | — |
Depreciation & Amortization vs competitors
How PROK compares with its peers on the latest reported figures
- PROK's LTM Mar 2026 depreciation & amortization of $6.02M is the 2nd highest of the 7 companies compared; the peer median is $1.41M.
- Its year-over-year change of +1.6% is the 4th highest of 6, against a peer median of +2.4%.
- Depreciation & amortization amounts to 677.4% of revenue for PROK, versus a peer median of 7.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $47.58M | -13.0% | +43.1% | 7.3% | |
| LTM Mar 2026 | $6.02M | +1.6% | +29.4% | 677.4% | |
| LTM Mar 2026 | $3.37M | +51.2% | +38.8% | 0.8% | |
| LTM Mar 2026 | $2.16M | -28.6% | -14.3% | 10.8% | |
| LTM Mar 2026 | $648K | +144.5% | +52.6% | — | |
| LTM Mar 2026 | $43K | +2.4% | +19.8% | — | |
| LTM Dec 2024 | $120 | — | -6.7% | — | |
| Peer median (excluding PROK) | $1.41M | +2.4% | +29.3% | 7.3% | |
Competitors are the stored peer set for PROK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 76K | 893K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 76K | 893K |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Research & Development | 46.26M | 82.07M | 106.71M | 127.67M | 114.12M |
| Selling, General & Admin | 8.86M | 70.94M | 44.82M | 56.08M | 51.78M |
| Operating Expenses | 55.11M | 153.01M | 151.52M | 183.75M | 165.9M |
| Depreciation & Amortization | 1.98M | 3.04M | 3.85M | 5.43M | 6.58M |
| EBITDA | (53.12M) | (143.99M) | (125.59M) | (158.49M) | (144.62M) |
| EBITDA Margin | — | — | — | -208542.1% | -16194.7% |
| Operating Income | (55.11M) | (153.01M) | (151.52M) | (183.68M) | (165.01M) |
| Operating Margin | — | — | — | -241678.9% | -18477.8% |
| Interest Income | 2K | 5.98M | 22.08M | 19.75M | 13.81M |
| Interest Expense | 0 | 215K | 12K | 9K | 4K |
| Other Income / Expenses | 2K | 5.77M | 22.07M | 19.74M | 13.81M |
| Income Before Tax | (55.11M) | (147.24M) | (129.45M) | (163.93M) | (151.2M) |
| Pre-Tax Margin | — | — | — | -215701.3% | -16931.5% |
| Income Tax Expense | 38K | 896K | 6M | (598K) | 414K |
| Net Income | (55.15M) | (108.03M) | (35.47M) | (61.19M) | (68.99M) |
| Net Margin | — | — | — | -80507.9% | -7725.2% |
| EPS (Basic) | (1.73) | (1.76) | (0.57) | (0.62) | (0.52) |
| EPS (Diluted) | (1.73) | (1.76) | (0.57) | (0.62) | (0.52) |
| Weighted Avg Shares | 31.89M | 61.54M | 61.71M | 97.92M | 133.94M |
| Weighted Avg Shares (Diluted) | 31.89M | 61.54M | 61.71M | 97.92M | 133.94M |
ProKidney Corp.
NASDAQ:PROK
Intrinsic Alpha fair value
Locked
Current Price
$1.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.